BCM
KRON

Bayesian Capital Management’s Kronos Bio KRON Stock Holding History

Bayesian Capital Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,400
Closed -$90K – 944
2022
Q1 		$90K Buy
+12,400
New +$106K 0.01% 704

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Bayesian Capital Management's KRON Position: Q2 2022 in Review

Bayesian Capital Management sold out of Kronos Bio (KRON) in Q2 2022, closing a stake of 12,400 shares — an estimated $90K sold.

Bayesian Capital Management first reported a position in KRON in Q1 2022 and held it in 1 quarter. The position peaked at $90K in Q1 2022. 93 funds tracked by Wall St. Rank hold KRON as of Q2 2022.

  • Bayesian Capital Management reported no remaining Kronos Bio position as of Q2 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 12,400 Kronos Bio shares in Q2 2022, an estimated $90K.
  • Bayesian Capital Management first reported a position in Kronos Bio in Q1 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Kronos Bio position peaked at $90K in Q1 2022.
  • 93 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.